Universidad de Granada Digibug

Repositorio Institucional de la Universidad de Granada >
1.-Investigación >
Departamentos, Grupos de Investigación e Institutos >
Departamento de Farmacología >
DF - Artículos >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10481/44560

Title: Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience
Authors: Marín Pozo, Juan Francisco
Duarte Pérez, Juan Manuel
Sánchez Rovira, Pedro
Issue Date: 2016
Abstract: To evaluate the safety and efficacy of bevacizumab in a broader patient population with solid tumors in the context of general clinical practice. Moreover, we quantified the economic impact and characterized the off-label use (OLU) of this agent in real-life prescribing practices. This is an open, retrospective, observational, real world study carried out at a regional Spanish hospital attending a population of 665,000 inhabitants. All of the patients receiving bevacizumab-containing therapy between January 2006 and February 2012 at the study hospital were included: no exclusion criteria were specified. All study variables were collected from available hospital records. The analysis comprised 240 episodes from 226 patients (male 41%; median age 57 years, 25% ≥65 years). Eighty cases (33%) of bevacizumab treatment were administered as first-line therapy. The median duration of bevacizumab treatment was 5.8 months (95% CI 5.1–6.6), without difference by age, line of treatment, or type of tumor. Typically bevacizumab-related toxicities included bleeding (25%), hypertension (5%), wound-healing complications (4%), gastrointestinal perforation (2%), and arterial thromboembolism (1%). Median progression-free survival was 7.5 months (95% CI 6.3–8.7) and median OS reached 13.1 months (95% CI 11.4–14.9). Bevacizumab increased the chemotherapy cost to 207% (from €3,115,615 to €9,552,405). Bevacizumab was prescribed off-label in 43% of episodes, amounting to €3,586,420 (56% of bevacizumab total cost). The efficacy and safety profile of bevacizumab in routine clinical practice is consistent with results observed in prospective randomized clinical trials. OLU of this drug should be closely monitored.
Publisher: Lippincott Williams and Wilkins
Keywords: Bevacizumab
URI: http://hdl.handle.net/10481/44560
ISSN: 0025-7974
Rights : Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Citation: Martín-Pozo, J.F.; Duarte-Pérez, J.M.; Sánchez-Rovira, P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine, 95(19): e3623 (2016). [http://hdl.handle.net/10481/44560]
Appears in Collections:DF - Artículos

Files in This Item:

File Description SizeFormat
MarinPozo_Bevacizumab.pdf461.8 kBAdobe PDFView/Open
Recommend this item

This item is licensed under a Creative Commons License
Creative Commons

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! OpenAire compliant DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback

© Universidad de Granada